Journal of Vaccines & Vaccination

Activation of protective innate-adaptive immunity duo for conferring rapid sustained broad protection of vaccines against pathogens

10^th Euro Global Summit and Expo on Vaccines & Vaccination

June 16-18, 2016 Rome, Italy

De-chu Christopher Tang

VaxDome LLC, USA

Posters & Accepted Abstracts: J Vaccines Vaccin

Abstract:

We report that intranasal administration of an E1/E3-defective (�?E1E3) adenovirus serotype 5 (Ad5) vectored influenza vaccine could induce seroconversion in human volunteers without appreciable adverse effects even in subjects with pre-existing Ad5 immunity. Mice and ferrets were well protected against challenge by a lethal dose of an H5N1 avian influenza virus following intranasal instillation of an Ad5 vector encoding hemagglutinin (HA) in a single dose regimen. Moreover, the �?E1E3 Ad5 particle itself without trans-gene could confer rapid sustained broad protection against influenza by inducing an anti-influenza state in a drug like manner, conceivably by activating a specific arm of innate immunity. An Ad5 vector encoding HA thus consolidates drug and vaccine into a single package which allows the Ad5 backbone to induce protective innate immunity capable of conferring nearly immediate and prolonged (e.g., 5 hours to 47 days) protection as the first wave against influenza followed by HA mediated adaptive immunity as the second wave before the innate immunity associated anti-influenza state declines away. In addition to �?E1E3 Ad5_s capacity to rapidly induce an anti-influenza state, an Ad5 vector encoding a bioengineered Bacillus anthracis protective antigen (PA) could also confer rapid (e.g., 1-2 days) prophylactic or post-exposure anthrax therapy with synergy to antibiotic treatment in a murine model. Both rabbits and macaques were well protected by an Ad5-PA vectored nasal anthrax vaccine in a single dose regimen against inhalational anthrax following challenge with a lethal dose of Bacillus anthracis Ames spores. Overall, the work conceivably would foster the development of a novel non-invasive drug-vaccine duo platform technology capable of conferring rapid sustained broad protection against pathogens with neither the potential to induce drug resistance nor that to trigger harmful systemic inflammation.

Biography :

Email: dechutang@gmail.com